作者: Min Han Lew , Mohd Nor Norazmi , Gee Jun Tye
DOI: 10.1016/J.MOLIMM.2019.10.023
关键词: Immunogenicity 、 Population 、 Immunology 、 Immunity 、 Humoral immunity 、 Cellular immunity 、 Antigen 、 Immune system 、 Adjuvant 、 Medicine 、 Molecular biology
摘要: Tuberculosis (TB) is one of the deadliest human diseases worldwide caused by mycobacterial infection in lung. Bacillus Calmette-Guerin (BCG) vaccine protects against disseminated TB children, but its effectiveness still questionable due to highly variable protections adolescence and elderly individuals. Targeting latency M.tb antigen a recent therapeutic approach eradicate dormant pathogen that could possibly lead disease activation. In this study, we aimed potentiate immune responses elicited 16 kDa α-crystalline (HspX) tuberculosis incorporation Combined Adjuvant for Synergistic Activation Cellular immunity (CASAC). Histidine-tagged recombinant HspX protein was initially produced Escherichia coli purified using Ni-NTA chromatography. To evaluate adjuvanticity, C57BL/6 mice (n = 5) were primed intradermally immunised 2-weeks interval 4 rounds with HspX, formulated without CASAC. Humoral cell-mediated evaluated ELISA Flow Cytometry. Our findings showed CASAC improved humoral increased antigen-specific IgG1 IgG2a antibody response. Stronger CD8+ Th1-driven induced formulation as supported elevated level IFN-γ, TNF-α, IL-12 IL-17A; low IL-10 secretion. Interestingly, adjuvanted triggered higher percentage effector memory T-cell population than those unadjuvanted vaccine. conclusion, adjuvant has great potential enhance immunogenicity antigen, which be an alternative regimen improve efficacy future Mycobacterium tuberculosis.